• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Aligos Therapeutics, Inc. - Common stock (NQ:ALGS)

    6.210 +0.120 (+1.97%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 55,403
    Open 6.150
    Bid (Size) 5.700 (100)
    Ask (Size) 6.550 (500)
    Prev. Close 6.090
    Today's Range 6.010 - 6.640
    52wk Range 3.980 - 13.69
    Shares Outstanding 42,940,089
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Discover the top movers in Wednesday's pre-market session. ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
    Gainers Can Fite Biopharma (AMEX:CANF) shares moved upwards by 20.4% to $3.96 during Wednesday's pre-market session. The company's market cap stands at $7.0 million. Aligos Therapeutics (NASDAQ:ALGS)... 
    Via Benzinga

    Performance

    YTD
    -32.0%
    -32.0%
    1 Month
    +35.0%
    +35.0%
    3 Month
    +18.3%
    +18.3%
    6 Month
    -9.3%
    -9.3%
    1 Year
    -41.5%
    -41.5%

    More News

    Read More
    News headline image
    Aligos Therapeutics to Present at the Cantor Global Healthcare Conference
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics (NASDAQ:ALGS) Surges After Hours on Q1 Earnings Beat ↗
    Via Chartmill
    Aligos Therapeutics Inc (NASDAQ:ALGS) Reports Q4 Revenue Miss, Highlights 2026 Clinical Catalysts ↗
    Via Chartmill
    Keep an eye on the top gainers and losers in Monday's session. ↗
    Via Chartmill
    News headline image
    Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection
    From Aligos Therapeutics
    Via GlobeNewswire
    The trading volume of these stocks is deviating from the norm in today's session. ↗
    Via Chartmill
    Monday's after hours session: top gainers and losers ↗
    Via Chartmill
    News headline image
    Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Presents Positive Data at the EASL Congress 2026
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics to Announce 4th Quarter 2025 Financial Results on March 5, 2026
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI)
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates
    From Aligos Therapeutics
    Via GlobeNewswire

    Frequently Asked Questions

    Is Aligos Therapeutics, Inc. - Common stock publicly traded?
    Yes, Aligos Therapeutics, Inc. - Common stock is publicly traded.
    What exchange does Aligos Therapeutics, Inc. - Common stock trade on?
    Aligos Therapeutics, Inc. - Common stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Aligos Therapeutics, Inc. - Common stock?
    The ticker symbol for Aligos Therapeutics, Inc. - Common stock is ALGS on the Nasdaq Stock Market
    What is the current price of Aligos Therapeutics, Inc. - Common stock?
    The current price of Aligos Therapeutics, Inc. - Common stock is 6.210
    When was Aligos Therapeutics, Inc. - Common stock last traded?
    The last trade of Aligos Therapeutics, Inc. - Common stock was at 09/02/26 04:00 PM ET
    What is the market capitalization of Aligos Therapeutics, Inc. - Common stock?
    The market capitalization of Aligos Therapeutics, Inc. - Common stock is 266.66M
    How many shares of Aligos Therapeutics, Inc. - Common stock are outstanding?
    Aligos Therapeutics, Inc. - Common stock has 267M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.